Following Wendy Dixon’s last INCY Sell transaction on November 21, 2011, the stock climbed by 73.0%. This is Dixon’s first transaction since reporting a Buy transaction on ALKS back in March 2014
Based on Incyte’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $552 million and quarterly net profit of $128 million. In comparison, last year the company earned revenue of $450 million and had a net profit of $29.18 million. The company has a one-year high of $89.30 and a one-year low of $57.00. INCY’s market cap is $17.83B and the company has a P/E ratio of 45.65.
In the last 30 days, insiders have sold $4.48M worth of INCY shares and purchased $5,032 worth of INCY shares. The insider sentiment on Incyte has been positive according to 105 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.